From the Editor

Oct 11, 2018
Pharmaceutical Executive
As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.
Sep 11, 2018
Pharmaceutical Executive
In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.
Aug 01, 2018
Pharmaceutical Executive
A common thread in our exploration of "Emerging Biopharma" is that these companies need to be those that look beyond pure discovery—and put equal effort into the pivot to potential commercialization.
Jul 09, 2018
Pharmaceutical Executive
With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?
Jun 11, 2018
Pharmaceutical Executive
Lisa Henderson reports on the takeaways from last month's annual gathering of the Pharm Exec Editorial Advisory Board.
May 08, 2018
Pharmaceutical Executive
Amid new efforts to inspire more physicians to engage their patients about clinical research, turning that vision into tangible gains in trial participation remains tricky.
Apr 09, 2018
Pharmaceutical Executive
Pharma's evolving landscape in recent years has created the need to recruit experts from outside of industry—and establish new pathways for traditional executive roles in the life sciences.
Mar 07, 2018
Pharmaceutical Executive
Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.
Feb 06, 2018
Pharmaceutical Executive
Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders—call it the quest to see "what right looks like?"
Jan 09, 2018
Pharmaceutical Executive
The advent of immunocellular therapies marks a major milestone in medical innovation, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance.
native1_300x100
lorem ipsum